Tag: LSP

Company News: LSP launches IPO of LSP Life Sciences Fund on NYSE Euronext

Having built an exceptional track record as one of Europe´s most successful and reputable investment firms in life sciences, LSP Life Sciences Partners has decided to set up a public fund, which has been taken public on NYSE Euronext today. The LSP Life Sciences Fund (ISIN: NL0009756394) is managed by Mark Wegter, Joep Muijrers and Geraldine O’Keeffe, all of which are seasoned investment professionals in the healthcare sector and have been responsible for LSP´s investments in public companies since 2008. Since then, the team has significantly outperformed the market and generated a return in excess of +150%, according to Mark Wegter.

The new fund takes a long-only investment strategy and allows generalist and retail investors to benefit from LSP´s outstanding expertise in life sciences – a highly complex and knowledge-driven sector.  While investing primarily in Europe, there will also be selected U.S. investments. The fund´s goal is to participate in all forms of primary or secondary offerings, including follow-on offerings, block trades and IPOs – given that the respective investee company passes the team´s strict, comprehensive diligence process, which is regarded as a key to success by LSP.

 

Company News: Okairos Raises €16 Million in Series B Financing

Swiss-Italian vaccine play Okairos today announced the closing of a €16 million series B financing round. The proceeds will be used to further advance Okairos’ product portfolio. The vaccines developed by Okairos are based on new, potent adenovirus vectors that can engage the cellular arms of the immune system to elicit a strong immune response involving T cells. The company is addressing major infectious diseases, e.g. malaria, HIV, hepatitis C and universal influenza. The financing was led by Versant Ventures and joined by the Boehringer Ingelheim Venture Fund. All existing investors – BioMedPartners, LSP and Novartis Venture Funds – also participated in the round. For further information, please visit the company’s website.